Cogent Biosciences, Inc.
COGT
Positions held
Your positionsCOGT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Cogent Biosciences operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and treatments, attracting significant investor interest.
- The company's market cap stands at approximately $5.27 billion, indicating a strong position in the market.
- Cogent has a target mean price of $55.82, suggesting a substantial upside potential from its current trading levels.
- Cogent Biosciences has reported zero revenue for multiple quarters, raising concerns about its operational viability.
- The company has a negative profit margin and has incurred net losses of over $328 million in 2025, highlighting ongoing financial struggles.
- With a score of -5.00 and a 'Sell' signal, the stock is currently viewed unfavorably by analysts, indicating potential risks for investors.
Fundamentals
| Market cap | $5.22B | Enterprise value | $4.74B | Trailing P/E | — | Forward P/E | -27.05 |
| PEG | — | Price / book | 11.04 | Beta | 0.31 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -109.7% | ROA | -43.8% | Debt / equity | 0.46 |
| Current ratio | 13.57 | Free cash flow | -$186.15M | Analyst recommendation | strong_buy | Mean target | $55.82 |
| 52w high | $43.73 | 52w low | $13.78 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$96.4M | -$97.4M | -$102M | -$80.9M | -$73.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$103M | -$104M | -$99.5M | -$83.4M | -$75.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$329M | -$256M | -$192M | -$140M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$333M | -$276M | -$208M | -$148M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
2026-09-24 · Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
2026-09-24 · Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
2026-09-15 · Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
2026-09-02 · Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
2026-08-31 · Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
2026-08-13 · Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-08-10 · Cogent Biosciences Q2 Loss Widens
2026-07-15 · Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib
Price (daily)
Full chart · RSI · MACD · patterns